Description

SIMPARICA TRIO 5 TO 10KG (1X3)

Indications

Simparica Trio is a veterinary medicinal product indicated for the treatment and prevention of flea infestations and the control of tick infestations in dogs. Specifically formulated for dogs weighing between 5 to 10 kg, it provides comprehensive protection against various ectoparasites. Additionally, Simparica Trio is effective in the treatment of intestinal nematodes, including roundworms and hookworms. This makes it a versatile option for pet owners looking to safeguard their canine companions from multiple parasitic threats.

Mechanism of Action

Simparica Trio combines three active ingredients: sarolaner, moxidectin, and pyrantel. Sarolaner is an ectoparasiticide that acts by inhibiting the function of gamma-aminobutyric acid (GABA) and glutamate-gated chloride channels in the nervous system of parasites, leading to their paralysis and death. Moxidectin, a member of the macrocyclic lactone class, works by binding to specific receptors in the nervous system of nematodes and arthropods, causing paralysis and subsequent death of these parasites. Pyrantel is a depolarizing neuromuscular blocking agent that causes paralysis in intestinal roundworms and hookworms, facilitating their expulsion from the gastrointestinal tract. Together, these active ingredients provide a synergistic effect, ensuring broad-spectrum efficacy against various parasites.

Pharmacological Properties

Simparica Trio is administered orally and is rapidly absorbed in the gastrointestinal tract. Sarolaner reaches peak plasma concentrations within a few hours, while moxidectin and pyrantel also exhibit quick absorption profiles. The product has a favorable pharmacokinetic profile, allowing for sustained efficacy over a month. The elimination half-lives of the active ingredients support once-monthly dosing, making it convenient for pet owners. The formulation is designed to ensure palatability, encouraging dogs to consume the chewable tablet easily.

Contraindications

Simparica Trio should not be administered to dogs that are hypersensitive to any of its active ingredients or to any of the excipients in the formulation. It is contraindicated in puppies younger than eight weeks of age and in dogs weighing less than 2.8 kg. Additionally, it should not be used in animals with a known history of seizures or neurological disorders, as the active ingredients may exacerbate these conditions.

Side Effects

While Simparica Trio is generally well tolerated, some dogs may experience mild side effects. Commonly reported adverse reactions include vomiting, diarrhea, lethargy, and decreased appetite. These side effects are typically transient and resolve without intervention. In rare cases, more serious side effects such as neurological signs (e.g., tremors, ataxia) may occur, particularly in dogs with pre-existing conditions. Pet owners should monitor their dogs for any unusual behavior following administration and consult a veterinarian if any concerning symptoms arise.

Dosage and Administration

The recommended dosage of Simparica Trio is based on the dog’s weight. For dogs weighing between 5 to 10 kg, the appropriate dosage is one chewable tablet once monthly. It is important to administer the product with food to enhance absorption and ensure optimal efficacy. The chewable tablet should be given whole and not divided or crushed, as this may affect the pharmacokinetics of the active ingredients. Regular administration is crucial for maintaining effective parasite control, and pet owners should establish a consistent monthly schedule for dosing.

Interactions

Simparica Trio has not been shown to have significant drug interactions with commonly used veterinary medications. However, caution should be exercised when administering it concurrently with other products that may have similar pharmacological effects, particularly those that affect the central nervous system. It is advisable to inform the veterinarian of any other medications or supplements the dog is receiving to ensure safe and effective use of Simparica Trio.

Precautions

Pet owners should take certain precautions when using Simparica Trio. Prior to administration, it is essential to conduct a thorough veterinary examination to rule out any underlying health issues that may contraindicate its use. Dogs with a history of seizures or neurological disorders should be monitored closely. Pregnant or lactating dogs should only receive this product under the guidance of a veterinarian. Additionally, it is crucial to keep the product out of reach of children and to follow proper disposal guidelines for any unused or expired medication.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of Simparica Trio in various canine populations. In controlled trials, the product showed a high level of efficacy in eliminating fleas and ticks within 24 hours of administration, with sustained protection lasting for a full month. Furthermore, studies indicated that Simparica Trio effectively treated and controlled intestinal nematodes, providing a comprehensive approach to parasite management. The safety profile was also evaluated, with adverse reactions being minimal and transient in nature. These studies support the use of Simparica Trio as a reliable option for pet owners seeking to protect their dogs from parasitic infestations.

Conclusion

Simparica Trio 5 to 10 kg (1X3) offers a multifaceted approach to parasite control in dogs, combining the efficacy of three active ingredients to address flea and tick infestations as well as intestinal nematodes. Its convenient once-monthly dosing, palatable formulation, and favorable safety profile make it an attractive choice for pet owners. As with any veterinary product, it is essential to follow the recommended guidelines for use and consult a veterinarian for personalized advice tailored to the individual needs of the dog.